Study: Open-label, randomized phase II trial Metastatic or unresectable colorectal cancer with bRAF-V600E mutation. Received one or more systemic therapy before Irinotecan – cetuximab + placebo (n=50) vs. Irinotecan –
Study: Open-label, phase 3 trial (BOSTON) Multiple myeloma progressed on or after last treatment regimen, previously received 1-3 regimens Selinexor – wkly bortezomib – dexamethasone (n=195) vs. twice wkly bortezomib
Study: Open-label, phase 3 trial Candidates for >=1 yr of continuous androgen-deprivation therapy Oral Relugolix (n=622) vs. leuprolide (n=308) Efficacy: Sustained testosterone suppression: 96.7% vs. 88.8% (non-inferior) Probability of castration
Study: Open-label phase 3 trial Previously untreated metastatic MSI-H-dMMR colorectal cancer Pembrolizumab 200 mg q21 (n=153) vs. investigator’s choice of chemo (n=154) Chemo: mFOLFOX6 or FOLFIRI alone or with bevacizumab
Study: Phase I/II, single arm (ARROW trial) Advanced RET mutation-positive RAI-refractory thyroid cancer (n=9, all had papillary thyroid cancer) Efficacy: ORR: 89% (52% – 100%), all PR Duration of response
Study: Phase I/II, single arm (ARROW trial) Advanced RET mutation-positive medullary thyroid cancer (MTC, n= 79). Previously treated with cabozantinib or vandetanib or both (n=55) Efficacy: ORR: 65% (overall, 53%-75%),
Privacy & Cookies Policy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.